Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient.

Miano ST, Francini E, Petrioli R, Francini G.

Future Oncol. 2020 Jan;16(1s):33-38. doi: 10.2217/fon-2019-0600.

PMID:
31975628
2.

Evaluation of the weight loss of raw beef cuts vacuumpackaged with two different techniques.

Stella S, Garavaglia D, Francini G, Viganò V, Bernardi C, Tirloni E.

Ital J Food Saf. 2019 Dec 5;8(4):8111. doi: 10.4081/ijfs.2019.8111. eCollection 2019 Dec 5.

3.

Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study.

Petrioli R, Mazzei MA, Giorgi S, Cesqui E, Gentili F, Francini G, Volterrani L, Francini E.

Anticancer Drugs. 2020 Feb;31(2):190-195. doi: 10.1097/CAD.0000000000000864.

PMID:
31850916
4.

Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer.

Petrioli R, Francini E, Cherri S, Marrelli D, Rovello F, Fiaschi AI, Miano ST, Savelli V, Calomino N, Farsi M, Vernillo R, Francini G.

Anticancer Drugs. 2019 Dec 14. doi: 10.1097/CAD.0000000000000877. [Epub ahead of print]

PMID:
31850915
5.

GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up.

Caraglia M, Correale P, Giannicola R, Staropoli N, Botta C, Pastina P, Nesci A, Caporlingua N, Francini E, Ridolfi L, Mini E, Roviello G, Ciliberto D, Agostino RM, Strangio A, Azzarello D, Nardone V, Falzea A, Cappabianca S, Bocchetti M, D'Arrigo G, Tripepi G, Tassone P, Addeo R, Giordano A, Pirtoli L, Francini G, Tagliaferri P.

Front Oncol. 2019 Nov 8;9:1102. doi: 10.3389/fonc.2019.01102. eCollection 2019.

6.

Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.

Petrioli R, Marrelli D, Roviello F, D'Ignazio A, Torre P, Chirra M, Savelli V, Ambrosio MR, Francini G, Calomino N, Farsi M, Vernillo R, Francini E.

Surg Oncol. 2019 Oct 2;32:2-7. doi: 10.1016/j.suronc.2019.10.002. [Epub ahead of print]

PMID:
31670056
7.

Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer.

Petrioli R, Torre P, Pesola G, Paganini G, Paolelli L, Miano ST, Martellucci I, Francini G, Francini E.

J Geriatr Oncol. 2019 Aug 27. pii: S1879-4068(19)30130-4. doi: 10.1016/j.jgo.2019.08.008. [Epub ahead of print]

PMID:
31471168
8.

Extramammary invasive Paget's disease and apocrine angiomatous hamartoma: an unusual association.

Miracco C, Francini E, Torre P, Baldino G, Chirra M, Cinotti E, Francini G.

Eur J Dermatol. 2018 Dec 1;28(6):853-855. doi: 10.1684/ejd.2018.3438. No abstract available.

PMID:
30514671
9.

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.

Passiglia F, Cappuzzo F, Alabiso O, Bettini AC, Bidoli P, Chiari R, Defferrari C, Delmonte A, Finocchiaro G, Francini G, Gelsomino F, Giannarelli D, Giordano M, Illiano A, Livi L, Martelli O, Natoli C, Puppo G, Ricevuto E, Roca E, Turci D, Galetta D.

Br J Cancer. 2019 Jan;120(1):57-62. doi: 10.1038/s41416-018-0234-3. Epub 2018 Oct 31.

10.

Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer.

Petrioli R, Francini E, Cherri S, Torre P, Fiaschi AI, Miano ST, Marrelli D, Rovello F, Francini G.

Clin Colorectal Cancer. 2018 Dec;17(4):e663-e669. doi: 10.1016/j.clcc.2018.07.002. Epub 2018 Jul 4.

PMID:
30153975
11.

Ectomycorrhizal Fungal Communities in Urban Parks Are Similar to Those in Natural Forests but Shaped by Vegetation and Park Age.

Hui N, Liu X, Kotze DJ, Jumpponen A, Francini G, Setälä H.

Appl Environ Microbiol. 2017 Nov 16;83(23). pii: e01797-17. doi: 10.1128/AEM.01797-17. Print 2017 Dec 1.

12.

Urban parks provide ecosystem services by retaining metals and nutrients in soils.

Setälä H, Francini G, Allen JA, Jumpponen A, Hui N, Kotze DJ.

Environ Pollut. 2017 Dec;231(Pt 1):451-461. doi: 10.1016/j.envpol.2017.08.010. Epub 2017 Aug 19.

PMID:
28830018
13.

Soil microbial communities are shaped by vegetation type and park age in cities under cold climate.

Hui N, Jumpponen A, Francini G, Kotze DJ, Liu X, Romantschuk M, Strömmer R, Setälä H.

Environ Microbiol. 2017 Mar;19(3):1281-1295. doi: 10.1111/1462-2920.13660. Epub 2017 Feb 1.

PMID:
28063185
14.

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

Cheung WY, Renfro LA, Kerr D, de Gramont A, Saltz LB, Grothey A, Alberts SR, Andre T, Guthrie KA, Labianca R, Francini G, Seitz JF, O'Callaghan C, Twelves C, Van Cutsem E, Haller DG, Yothers G, Sargent DJ.

J Clin Oncol. 2016 Apr 10;34(11):1182-9. doi: 10.1200/JCO.2015.65.1158. Epub 2016 Feb 8.

15.

Arbuscular mycorrhizal fungal community divergence within a common host plant in two different soils in a subarctic Aeolian sand area.

Francini G, Männistö M, Alaoja V, Kytöviita MM.

Mycorrhiza. 2014 Oct;24(7):539-50. doi: 10.1007/s00572-014-0573-8. Epub 2014 Apr 1.

PMID:
24687606
16.

Sjögren's syndrome and aromatase inhibitors treatment: is there a link?

Guidelli GM, Martellucci I, Galeazzi M, Francini G, Fioravanti A.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4):653-4. Epub 2013 Apr 3. No abstract available.

PMID:
23558055
17.

CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.

Petrioli R, Licchetta A, Roviello G, Pascucci A, Francini E, Bargagli G, Conca R, Miano ST, Marzocca G, Francini G; Multidisciplinary Oncology Group On Gastrointestinal Tumors.

Cancer Invest. 2012 Jan;30(1):65-71. doi: 10.3109/07357907.2011.629380.

PMID:
22236191
18.

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.

Petrioli R, Pascucci A, Conca R, Chiriacò G, Francini E, Bargagli G, Fiaschi AI, Manganelli A, De Rubertis G, Barbanti G, Ponchietti R, Francini G.

Br J Cancer. 2011 Feb 15;104(4):613-9. doi: 10.1038/bjc.2011.5. Epub 2011 Feb 1.

19.

Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.

Vincenzi B, Galluzzo S, Santini D, Rocci L, Loupakis F, Correale P, Addeo R, Zoccoli A, Napolitano A, Graziano F, Ruzzo A, Falcone A, Francini G, Dicuonzo G, Tonini G.

Ann Oncol. 2011 May;22(5):1141-6. doi: 10.1093/annonc/mdq550. Epub 2010 Nov 29.

PMID:
21115601
20.

Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.

Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, Rotundo MS, Tassone P, Sperlongano P, Abbruzzese A, Caraglia M, Tagliaferri P, Francini G.

Cancer Biol Ther. 2010 May 1;9(9):685-93.

PMID:
20697196
21.

Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate.

Licchetta A, Correale P, Migali C, Remondo C, Francini E, Pascucci A, Magliocca A, Guarnieri A, Savelli V, Piccolomini A, Carli AF, Francini G.

J Chemother. 2010 Jun;22(3):201-4.

PMID:
20566427
22.

Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.

Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, Tsang KY, Licchetta A, Mannucci S, Loiacono L, Tassone P, Francini G, Tagliaferri P.

J Immunother. 2010 May;33(4):435-41. doi: 10.1097/CJI.0b013e3181d32f01.

PMID:
20386463
23.

A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity.

Montagnani F, Chiriatti A, Turrisi G, Francini G, Fiorentini G.

Colorectal Dis. 2011 Aug;13(8):846-52. doi: 10.1111/j.1463-1318.2010.02206.x. Epub 2010 Jan 12. Review.

PMID:
20070327
24.

Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.

Petrioli R, Bargagli G, Lazzi S, Pascucci A, Francini E, Bellan C, Conca R, Martellucci I, Fiaschi AI, Lorenzi B, Francini G; Multidisciplinary Oncology Group in Gastrointestinal Tumors.

Anticancer Drugs. 2010 Mar;21(3):313-9. doi: 10.1097/CAD.0b013e328334d88a.

PMID:
20016369
25.

Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.

Correale P, Tindara Miano S, Remondo C, Migali C, Rotundo MS, Macrì P, Tagliaferri P, Caraglia M, Gotti G, Francini G.

Cancer Biol Ther. 2009 Mar 15;8(6):497-502. doi: 10.4161/cbt.8.6.7593. Epub 2009 Mar 15.

PMID:
19242101
26.

Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.

Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, de Gramont A.

J Clin Oncol. 2009 Feb 20;27(6):872-7. doi: 10.1200/JCO.2008.19.5362. Epub 2009 Jan 5.

27.

The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.

Petrioli R, Fiaschi AI, Francini E, Pascucci A, Francini G.

Cancer Treat Rev. 2008 Dec;34(8):710-8. doi: 10.1016/j.ctrv.2008.05.004. Epub 2008 Jul 11. Review.

PMID:
18620815
28.

Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial).

Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, Rotundo MS, Ginanneschi C, Martellucci I, Francini E, Cusi MG, Tassone P, Francini G.

Clin Cancer Res. 2008 Jul 1;14(13):4192-9. doi: 10.1158/1078-0432.CCR-07-5278.

29.

Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.

Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Savellini GG, Terrosi C, Mannucci S, Giorgi G, Francini G, Cusi MG.

J Immunother. 2008 Feb-Mar;31(2):132-47. doi: 10.1097/CJI.0b013e31815b69c8.

PMID:
18481383
30.

Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen.

Correale P, Fioravanti A, Bertoldi I, Montagnani F, Miracco C, Francini G.

J Chemother. 2008 Apr;20(2):278-81.

PMID:
18467257
31.

Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.

Correale P, Montagnani F, Miano S, Sciandivasci A, Pascucci A, Petrioli R, Testi W, Tanzini G, Francini G.

J Chemother. 2008 Feb;20(1):119-25.

PMID:
18343754
32.

Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine.

Correale P, Del Vecchio MT, Renieri T, Di Genova G, La Placa M, Remondo C, Savellini GG, Terrosi C, Zurbriggen R, Amacker M, Francini G, Cusi MG.

Cancer Lett. 2008 May 18;263(2):291-301. doi: 10.1016/j.canlet.2008.01.018. Epub 2008 Mar 4.

PMID:
18291576
33.

Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.

Petrioli R, Pascucci A, Francini E, Marsili S, Fiaschi AI, Civitelli S, Tanzini G, Battistelli S, Lorenzi M, Roviello F, Francini G; Multidisciplinary Oncology Group on Gastrointestinal Tumors.

Anticancer Drugs. 2008 Jan;19(1):91-6.

PMID:
18043134
34.

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A; ACCENT Group.

J Clin Oncol. 2007 Oct 10;25(29):4569-74. Epub 2007 Sep 17.

PMID:
17876008
35.

Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.

Petrioli R, Paolelli L, Francini E, Marsili S, Pascucci A, Sciandivasci A, de Rubertis G, Barbanti G, Manganelli A, Salvestrini F, Francini G.

Anticancer Drugs. 2007 Aug;18(7):817-20.

PMID:
17581304
36.

Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel.

Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, De Rubertis G, Barbanti G, Manganelli A, Salvestrini F, Francini G.

BJU Int. 2007 Oct;100(4):775-9. Epub 2007 May 29.

37.

Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer.

Francini G, Paolelli L, Francini E, Pascucci A, Manganelli A, Salvestrini F, Petrioli R.

Eur J Surg Oncol. 2008 Feb;34(2):216-21. Epub 2007 May 14.

PMID:
17502132
38.

Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation.

Correale P, Sciandivasci A, Intrivici C, Pascucci A, Del Vecchio MT, Marsili S, Savelli V, Voltolini L, Di Bisceglie M, Guarnieri A, Gotti G, Francini G.

Br J Cancer. 2007 May 7;96(9):1343-7. Epub 2007 Apr 17.

39.

Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.

Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R, Civitelli S, Tanzini G, Lorenzi M, Francini G.

Cancer Chemother Pharmacol. 2008 Jan;61(1):105-11. Epub 2007 Apr 12.

PMID:
17429632
40.

Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer.

Petrioli R, Paolelli L, Francini E, Manganelli A, Salvestrini F, Francini G.

Urology. 2007 Jan;69(1):142-6.

PMID:
17270637
41.

FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer.

Petrioli R, Paolelli L, Marsili S, Civitelli S, Francini E, Cioppa T, Roviello F, Nettuno R, Intrivici C, Tanzini G, Lorenzi M, Francini G.

Oncology. 2006;70(5):345-50. Epub 2006 Dec 15.

PMID:
17179728
42.

Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.

Gonnelli S, Cadirni A, Caffarelli C, Petrioli R, Montagnani A, Franci MB, Lucani B, Francini G, Nuti R.

Bone. 2007 Jan;40(1):205-10. Epub 2006 Aug 14.

PMID:
16904960
43.

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.

Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, Gonnelli S.

Br J Cancer. 2006 Jul 17;95(2):153-8.

44.

A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients.

Correale P, Cerretani D, Remondo C, Martellucci I, Marsili S, La Placa M, Sciandivasci A, Paolelli L, Pascucci A, Rossi M, Di Bisceglie M, Giorgi G, Gotti G, Francini G.

Oncol Rep. 2006 Jul;16(1):133-40.

PMID:
16786136
45.

Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience.

Correale P, Cusi MG, Micheli L, Nencini C, Del Vecchio MT, Torino F, Aquino A, Bonmassar E, Francini G, Giorgi G.

Invest New Drugs. 2006 Mar;24(2):99-110. Review.

PMID:
16502353
46.

Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation.

Caraglia M, Marra M, Budillon A, Meo G, Ricciardiello F, Bismuto E, Brachelente G, Francini G, Giordano A, Correale P, Abbruzzese A.

Cancer Biol Ther. 2005 Oct;4(10):1159-67. Epub 2005 Oct 23.

PMID:
16294035
47.

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A.

J Clin Oncol. 2005 Dec 1;23(34):8664-70. Epub 2005 Oct 31.

PMID:
16260700
48.

5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.

Correale P, Del Vecchio MT, Di Genova G, Savellini GG, La Placa M, Terrosi C, Vestri M, Urso R, Lemonnier F, Aquino A, Bonmassar E, Giorgi G, Francini G, Cusi MG.

J Natl Cancer Inst. 2005 Oct 5;97(19):1437-45.

PMID:
16204693
49.

Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer.

Petrioli R, Sabatino M, Roviello F, Marrelli D, Nastri G, Marsili S, Correale P, Pozzessere D, Messinese S, De Martino A, Tani F, Marzocca G, Lorenzi M, Civitelli S, Tanzini G, Pinto E, Francini G.

Hepatogastroenterology. 2005 Sep-Oct;52(65):1626-30.

PMID:
16201130
50.

Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.

Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G.

J Clin Oncol. 2005 Dec 10;23(35):8950-8. Epub 2005 Aug 1.

PMID:
16061910

Supplemental Content

Loading ...
Support Center